Lercanidipino Tarbis (Lercanidipine)

Lercanidipine is a calcium channel blocker used to manage conditions related to elevated vascular resistance.

• Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Isolated systolic hypertension: reduces elevated systolic pressure, particularly in older adults.
• Hypertension as adjunct therapy: may be combined with other antihypertensives to achieve target blood pressure.

• Lercanidipine selectively inhibits L-type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for muscle contraction. This leads to relaxation of arterial smooth muscle, resulting in vasodilation and a subsequent reduction in systemic vascular resistance and arterial blood pressure.

Lercanidipine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Headache: mild to moderate headache occurring shortly after dose initiation.
• Flushing: transient warmth and redness of the skin, especially on the face and neck.
• Peripheral edema: swelling of the ankles or lower legs due to fluid accumulation.
• Dizziness: sensation of light‑headedness, particularly when standing quickly.
• Tachycardia: increased heart rate, often accompanying vasodilation.
• Palpitations: awareness of irregular or forceful heartbeats.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may compromise airway.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Myocardial infarction: rare occurrence of heart attack, especially in patients with pre‑existing coronary disease.
• Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury.
• Allergic reactions: rash, itching, or severe hypersensitivity responses.

When prescribing Lercanidipine, clinicians should consider several safety measures.

• Blood pressure monitoring: measure baseline and periodic readings to assess therapeutic response.
• Concomitant CYP3A4 inhibitors: avoid or adjust dose when drugs like ketoconazole are co‑administered.
• Renal impairment: use with caution in patients with reduced kidney function.
• Elderly patients: initiate therapy at the lowest recommended dose.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at ambient temperature: keep below 25 °C, retain in the original pack, and protect from moisture.

Lercanidipine can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Grapefruit juice: can raise drug exposure and risk of hypotension.
• Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- Diuretics: additive blood‑pressure lowering effect; monitor for excessive hypotension.

• Beta‑blockers: combined effect on heart rate and blood pressure; observe patient response.
• ACE inhibitors/ARBs: increased risk of hypotension; adjust therapy as needed.